/ EN

Xuebin Liao, Ph.D.

(Summary description)Scientific Founder in immunotherapy</br></br>
</br></br></br></br></br></br></br></br></br>

*****
Xuebin Liao obtained his B.S. degree from Peking University in 1995. Then he did his Ph.D work on natural product synthesis with Prof. James M. Cook at the University of Wisconsin at Milwaukee from 1998-2004. After that, from 2005-2008, he was a postdoctoral associate with Prof. John F. Hartwig at Yale and later at UIUC. In 2009, he held a position of Research Investigator at GNF (the Genomics Institute of the Novartis Research Foundation). In September of 2012, he joined the Department of Pharmacology and Pharmaceutical Science, School of Medicine, Tsinghua University. Now Liao is a Professor in the School of Pharmaceutical Science, Beijing Advanced Innovation Center for Human Brain Protection, Tsinghua University, where his researches focuses on three major areas: (1) bioactive natural-product-oriented synthesis and the development of new synthetic methods, (2) immuno-oncology projects related to T-cell exhaustion and innate immunity, and (3) structure-based drug discovery. He published over 50 peer reviewed papers in journals, Including Nature, Cancer Cell, Science Translational Medicine, JACS, Science Advance, Angew Chem Int Ed et al.

Xuebin Liao, Ph.D.

(Summary description)Scientific Founder in immunotherapy</br></br>
</br></br></br></br></br></br></br></br></br>

*****
Xuebin Liao obtained his B.S. degree from Peking University in 1995. Then he did his Ph.D work on natural product synthesis with Prof. James M. Cook at the University of Wisconsin at Milwaukee from 1998-2004. After that, from 2005-2008, he was a postdoctoral associate with Prof. John F. Hartwig at Yale and later at UIUC. In 2009, he held a position of Research Investigator at GNF (the Genomics Institute of the Novartis Research Foundation). In September of 2012, he joined the Department of Pharmacology and Pharmaceutical Science, School of Medicine, Tsinghua University. Now Liao is a Professor in the School of Pharmaceutical Science, Beijing Advanced Innovation Center for Human Brain Protection, Tsinghua University, where his researches focuses on three major areas: (1) bioactive natural-product-oriented synthesis and the development of new synthetic methods, (2) immuno-oncology projects related to T-cell exhaustion and innate immunity, and (3) structure-based drug discovery. He published over 50 peer reviewed papers in journals, Including Nature, Cancer Cell, Science Translational Medicine, JACS, Science Advance, Angew Chem Int Ed et al.

Information

 

 

 

Xuebin Liao, Ph.D.

 

董事,免疫药物首席科学家

 

清华大学药学院教授、博士导师。1995年获得北京大学化学与分子工程学院学士,2004年获得威斯康星大学密尔沃基分校有机化学博士;2005-2008年期间随世界著名化学家 John F. Hartwig先后在耶鲁大学以及伊利诺伊大学香槟分校从事博士后研究;2009年至2012年在诺华功能基因组研究院(GNF)以高级研究员的身份开展药学研究。廖学斌于2012年入选第7批“千人计划(青年项目)”,2018年获“Roche Chinese Investigator Award”,2020年获“The Thieme Chemistry Journals Award”。廖学斌博士的研究兴趣涵盖化学,药学,化学生物学与免疫学等方面,发表科学论文50多篇,申请专利8项。在药物化学方向,基于靶点的结构信息,设计了几类小分子免疫调节剂,其中包括:TLR2、TLR7和TLR8的小分子激动剂, IRAK4小分子抑制剂,HPK1的小分子抑制剂和GLK小分子抑制剂,这些不同的小分子免疫调节剂在肿瘤免疫治疗以及自身免疫病的治疗中具有巨大的潜在临床价值。通过对T细胞衰竭机制的研究,证实了HPK1是调控T细胞衰竭的关键激酶,为实体瘤的CAR-T治疗带来新的思路。

 

imgboxbg

Home   丨   About Us   丨   Product and Pipeline   丨   Our Team   丨   News   丨   Career   丨   Contact

Address: 106 Fengze East Road, Nansha District, Guangzhou 
Email: ming-med@ming-med.com

Copyright © 2020 ming-med.com  保留所有权利  粤ICP备20029450号-1